Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas

Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas

Background. Epidermal growth factor receptor is overexpressed in most pediatric high-grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted a phase II trial of erlotinib and local radiotherapy in children with newly diagnosed HGG. <br/>Methods. Following maxim...

Full description

Bibliographic Details
Main Authors: Ibrahim eQaddoumi, Mehmet eKocak, Atmaram S. Pai-Panandiker, Gregory T. Armstrong, Cynthia eWetmore, John R. Crawford, Tong eLin, James M Boyett, Larry E. Kun, Fredrick A. Boop, Thomas E. Merchant, David W Ellison, Amar eGajjar, Alberto eBroniscer
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-04-01
Series:Frontiers in Oncology
Subjects:
Radiotherapy
pediatric
epidermal growth factor receptor
erlotinib
high-grade glioma
phase II
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00067/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00067/full

Similar Items